The overall survival (OS)of Chronic myeloid leukemia (CML) has been significantly improved since the advent of Tyrosine kinase inhibitors (TKIs) .Nevertheless, there still exists a amount of patients who has poor response or intolerance for TKI drugs( Imatinib, dasatinib, nilotinib). Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib,and it aslo has better security when compared to other TKIs(Imatinib, dasatinib, nilotinib).It will be a better chioce for CML patients.
Description: MMR(BCR/ABL(IS)<0.1%) at 12 months after treating
Measure: MMR rates at 12 months Time: 12 montsDescription: VEMR((BCR-ABL1/ABL1≤ 40% on the International Scale) at 4weeks after treating
Measure: VEMR rates at 4 weeks Time: 4 weeksCohort
There is one SNP
The pregnant test of female patients was negative (within 7 days before medication before enrollment); 6. Informed consent of the patient or his legal representative Exclusion Criteria: 1. T315I mutation is known to exist; 2. Rare atypical transcript types that cannot be standardized internationally; 3. Received TKI drugs for more than 2 weeks before enrollment; 4. Received interferon therapy for more than 3 months before enrollment; 5. Received other anti-CML drugs (except hydroxyurea) for more than 2 weeks or surgical treatment (including hematopoietic stem cell transplantation) 6. patients who participate in other clinical studies at the same time; 7. patients who having had major surgery or not recovered from surgery within 4 weeks; 8. patients who having history of malignant tumor 9. Woman who is pregnant or nursing 10. --- T315I ---